PHARMACY

Lupin launches Temovate generic

BY Brian Berk

BALTIMORE — Lupin has launched its Clobetasol Propionate Topical Solution USP, 0.05%.

Clobetasol is the generic equivalent of Fougera Pharmaceuticals’ Temovate (clobetasol propionate) Scalp Application, 0.05%. It is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.

Temovate Clobetasol Propionate Scalp Application had an estimated U.S. sales of USD 64.1 million in 2016.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Hy-Vee switches up Amber Pharmacy leadership

BY David Salazar
WEST DES MOINE, Ia. — Hy-Vee on Monday announced a change of leadership at Amber Pharmacy. The company has named Aaron Wiese, previously Hy-Vee assistant VP and Amber Pharmacy president, to the position of Hy-Vee VP strategy/innovation, and as a result, Mike Agostino has returned to the position of president of Amber Pharmacy.
Aaron Wiese
“Aaron has done an incredible job helping us to adapt Amber and Hy-Vee Pharmacy Solutions to the Hy-Vee system,” Hy-Vee chairman, CEO and president Randy Edeker said. “He has worked hand-in-hand with Mike to get Amber recognized as a customer service leader in specialty pharmacy, and he is the right person to keep us agile and take advantage of the industry’s fast-changing opportunities.”
In his new role, Wiese will work within Hy-Vee to develop new health, wellness and pharmacy strategies. He will also work with Agostino, the company said.
Mike Agostino
“Mike is one of the most respected voices in the industry nationwide. He has helped lead our specialty pharmacy efforts to great heights and will continue to do so while back in the driver’s seat at Amber Pharmacy and Hy-Vee Pharmacy Solutions,” Edeker said.
Amber Pharmacy was acquired by Hy-Vee in 2014 after the companies’ collaboration on Hy-Vee Pharmacy. Agostino has been with Amber Pharmacy since 2008, having worked previously as Walgreens’ VP managed care. He became VP of Hy-Vee and Amber Pharmacy president in 2014 and moved into his pharmacy innovation/business development role last January. He is the president-elect of the National Association of Specialty Pharmacy and instructs at the University of Nebraska Medical Center’s pharmacy program.
Wiese joined Hy-Vee in 1993 and served for four years as operations manager of Hy-Vee Care. Before becoming assistant VP specialty pharmacy and VP of Amber Pharmacy, he worked in health/wellness strategic planning. He became COO at Amber before becoming president in 2016.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Study: Non-EpiPen prescriptions quadruple

BY Brian Berk

WOONSOCKET, R.I. — Prescriptions for EpiPen alternatives have quadrupled since quadrupled since the beginning of 2017, with non-EpiPen epinephrine auto-injector prescriptions share reaching 28.9% for the period of Feb. 1-Feb. 25, according to athenaResearch.

Researchers analyzed more than 60,000 prescriptions for epinephrine auto-injectors since the beginning of 2016, written for 50,000 patients by more than 1,400 providers nationwide. In January 2016, just 4.8% of epinephrine auto-injector prescriptions were not for Mylan’s EpiPen. And throughout 2016, although non-EpiPen share reached as high as 7.8%, it ended the year at a 5.3% share in December. However, the share rose to 14.8% in January of this year and increased to a 28.9% share last month.

“Why the sudden, significant shift?” asked the report. “Patients and providers might be reaching for the alternatives and generics that have recently hit the shelves, as the industry responds to widespread demand.”

As Drug Store News reported, CVS Health is among those providing an EpiPen alternative, which sells for $109.99 for a two-pack.

The research can be found here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?